Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Al/ML Data sets
new
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2017
Pharma News, 2017
Sanofi/Regeneron’s ‘breakthrough’ PD-1 hits positive notes in skin cancer
Despite being late to market, the collaborators hope a new indication could help boost its prospects.
Needle-free injection device moves closer to market
Needles are usually seen as a necessary evil, but maybe they don't have to be.
University of Wollongong's PICT 3D bioprinter could revolutionize Type 1 diabetes treatment
Australia’s University of Wollongong (UOW) is quickly becoming a pioneer in 3D bioprinting technologies.
China: Minority Region Collects DNA from Millions
(New York) – Chinese authorities in Xinjiang are collecting DNA samples, fingerprints, iris scans, and blood types of all residents in the region between the age of 12 and 65, Human Rights W...
Amneal launches generic Kenalog-40
Amneal Biosciences is launching its generic of Kenalog-40 (triamcinolone acetonide injectable suspension, 40 mg/ml), with the Food and Drug Administration approved Tuesday.
Daiichi Sankyo signs up on two oncology deals
First up, Daiichi Sankyo and Puma Biotechnology (Nasdaq.
Otsuka returns US rights to Sativex
UK-based biopharma firm GW Pharmaceuticals (Nasdaq.
Currently 940 clinical stage immuno-oncology agents being developed, report
The USA-based Cancer Research Institute (CRI) last week published a report that provides a first-of-its-kind independent analysis of the global immuno-oncology (I-O) landscape, from ag...
FDA Approves Mepolizumab for Churg-Strauss (EGPA)
The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously kno...
Novel MDD Treatment Succeeds in Phase 2 Trial
A novel type of treatment for major depressive disorder (MDD) achieved the main goal of a phase 2 trial, reducing symptoms during a 2-week treatment period.
Promising responses seen with Agios leukemia drug in study
(Reuters) - Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experim...
Teva's job-cut tally could touch 10K: report
It’s no secret that Teva’s about to unveil some major layoffs.
1
2
3
4
5
6
7
8
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Al/ML Data sets
Synthetic and Medicinal Chemistry
In silico drug design (CADD)
Discovery biology
ADME, DMPK
Functional ex vivo and in vivo models
Safety and Toxicology
Company
News & Media
Contact us
Trends in discovery compounds